The US Food and Drug Administration has approved Afstyla (antihemophilic Factor [recombinant], single chain), a novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A from CSL Behring, a subsidiary of Australia’ CSL Limited (ASX: CSL)..
Afstyla is indicated in adults and children with hemophilia A for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and the perioperative management of bleeding. Afstyla is expected to be available in the USA early this summer, the company said.
"For 100 years, CSL has focused on researching and developing innovative therapies that meet the treatment challenges patients face,” said Andrew Cuthbertson, chief scientific officer and Director of R&D, CSL Limited. "The approval of Afstyla, an innovative and effective hemophilia A therapy, further demonstrates CSL’s dedication to developing and delivering novel therapies that have the potential to improve patients’ lives. We are very excited to add this treatment to our industry-leading portfolio of coagulation therapies and look forward to the positive impact Afstyla can have on patients with hemophilia A,” Dr Cuthbertson added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze